Small-Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System

被引:161
作者
Buckley, Dennis L. [1 ,2 ,3 ]
Crews, Craig M. [1 ,2 ,3 ]
机构
[1] Yale Univ, Dept Chem, New Haven, CT 06511 USA
[2] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06511 USA
[3] Yale Univ, Dept Pharmacol, New Haven, CT 06511 USA
关键词
drug design; inhibitors; proteasome; protein degradation; ubiquitin; ARYL-HYDROCARBON RECEPTOR; STRUCTURE-BASED DESIGN; ACTIVATING ENZYME E1; 20; S-PROTEASOME; CRYSTAL-STRUCTURE; NATURAL-PRODUCTS; DRUG DISCOVERY; NEDD8-ACTIVATING ENZYME; IRREVERSIBLE INHIBITOR; ALLOSTERIC INHIBITOR;
D O I
10.1002/anie.201307761
中图分类号
O6 [化学];
学科分类号
070301 [无机化学];
摘要
Traditionally, biological probes and drugs have targeted the activities of proteins (such as enzymes and receptors) that can be readily controlled by small molecules. The remaining majority of the proteome has been deemed "undruggable". By using small-molecule modulators of the ubiquitin proteasome, protein levels, rather than protein activity, can be targeted instead, thus increasing the number of druggable targets. Whereas targeting of the proteasome itself can lead to a global increase in protein levels, the targeting of other components of the UPS (e.g., the E3 ubiquitin ligases) can lead to an increase in protein levels in a more targeted fashion. Alternatively, multiple strategies for inducing protein degradation with small-molecule probes are emerging. With the ability to induce and inhibit the degradation of targeted proteins, small-molecule modulators of the UPS have the potential to significantly expand the druggable portion of the proteome beyond traditional targets, such as enzymes and receptors.
引用
收藏
页码:2312 / 2330
页数:19
相关论文
共 181 条
[1]
Development of the proteasome inhibitor PS-341 [J].
Adams, J .
ONCOLOGIST, 2002, 7 (01) :9-16
[2]
Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer [J].
Adams, J .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (04) :493-500
[3]
Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids [J].
Adams, J ;
Behnke, M ;
Chen, SW ;
Cruickshank, AA ;
Dick, LR ;
Grenier, L ;
Klunder, JM ;
Ma, YT ;
Plamondon, L ;
Stein, RL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (04) :333-338
[4]
Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase [J].
Aghajan, Mariam ;
Jonai, Nao ;
Flick, Karin ;
Fu, Fei ;
Luo, Manlin ;
Cai, Xiaolu ;
Ouni, Ikram ;
Pierce, Nathan ;
Tang, Xiaobo ;
Lomenick, Brett ;
Damoiseaux, Robert ;
Hao, Rui ;
del Moral, Pierre M. ;
Verma, Rati ;
Li, Ying ;
Li, Cheng ;
Houk, Kendall N. ;
Jung, Michael E. ;
Zheng, Ning ;
Huang, Lan ;
Deshaies, Raymond J. ;
Kaiser, Peter ;
Huang, Jing .
NATURE BIOTECHNOLOGY, 2010, 28 (07) :738-U1750
[5]
Differential Trafficking of Transport Vesicles Contributes to the Localization of Dendritic Proteins [J].
Al-Bassam, Sarmad ;
Xu, Min ;
Wandless, Thomas J. ;
Arnold, Don B. .
CELL REPORTS, 2012, 2 (01) :89-100
[6]
Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes [J].
Altun, Mikael ;
Kramer, Holger B. ;
Willems, Lianne I. ;
McDermott, Jeffrey L. ;
Leach, Craig A. ;
Goldenberg, Seth J. ;
Kumar, K. G. Suresh ;
Konietzny, Rebecca ;
Fischer, Roman ;
Kogan, Edward ;
Mackeen, Mukram M. ;
McGouran, Joanna ;
Khoronenkova, Svetlana V. ;
Parsons, Jason L. ;
Dianov, Grigory L. ;
Nicholson, Benjamin ;
Kessler, Benedikt M. .
CHEMISTRY & BIOLOGY, 2011, 18 (11) :1401-1412
[7]
[Anonymous], 2005, ANGEW CHEM, V117, P6082
[8]
[Anonymous], ANGEW CHEM
[9]
[Anonymous], 2008, ANGEW CHEM, DOI DOI 10.1002/ANGE.200802651
[10]
[Anonymous], ANGEW CHEM